Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Biological markers

Tailoring treatment and trials to prognosis

As we learn more about the biology of cancer, we may be able to apply prognostic biomarkers to select patients at high risk or low risk of disease recurrence or progression. This will allow a priori stratification of patients in clinical trials and will help to tailor treatment to patients.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1: Molecular prognostic and pathology algorithm for colon cancer.


  1. 1

    Schmoll, H. J. et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann. Oncol. 23, 2479–2516 (2012).

    CAS  Article  Google Scholar 

  2. 2

    La Thangue, N. B. & Kerr, D. J. Predictive biomarkers: a paradigm shift towards personalized cancer medicine. Nat. Rev. Clin. Oncol. 8, 587–596 (2011).

    CAS  Article  Google Scholar 

  3. 3

    Hutchins, G. et al. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J. Clin. Oncol. 29, 1261–1270 (2011).

    Article  Google Scholar 

  4. 4

    Salazar, R. et al. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J. Clin. Oncol. 1, 17–24 (2011).

    Article  Google Scholar 

  5. 5

    Gray, R. G. et al. Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer. J. Clin. Oncol. 29, 4611–4619 (2011).

    Article  Google Scholar 

  6. 6

    Huijbers, A. et al. The proportion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients: validation in the VICTOR trial. Ann. Oncol. 24, 179–185 (2013).

    CAS  Article  Google Scholar 

  7. 7

    Domingo, E. et al. Use of multivariate analysis to suggest a new molecular classification of colorectal cancer. J. Pathol. 229, 441–448 (2013).

    CAS  Article  Google Scholar 

  8. 8

    Kerr, D. J. & Midgley, R. Defective mismatch repair in colon cancer: a prognostic or predictive biomarker? J. Clin. Oncol. 28, 3210–3212 (2010).

    CAS  Article  Google Scholar 

  9. 9

    Peto, R. et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. Br. J. Cancer 34, 585–612 (1976).

    CAS  Article  Google Scholar 

  10. 10

    Van Cutsem, E. et al. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J. Clin. Oncol. 27, 3117–3125 (2009).

    CAS  Article  Google Scholar 

Download references


The authors thank Ian Tomlinson, Nicholas B. La Thangue and Rachel Midgley for valuable scientific discussions while writing this manuscript.

Author information



Corresponding author

Correspondence to David J. Kerr.

Ethics declarations

Competing interests

D. J. Kerr has received educational grants and speakers honorarium from Genomic Health and is a Director of Oxford Cancer Biomarkers. Y. Shi declares no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Kerr, D., Shi, Y. Tailoring treatment and trials to prognosis. Nat Rev Clin Oncol 10, 429–430 (2013).

Download citation

Further reading


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing